4 stories mentioning BOM:533229Updated 61d ago
Every FINWIRES story that references BOM:533229, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Bajaj Consumer Care (BOM:533229, NSE:BAJAJCON) has an average rating of buy and mean price target of 574.25 Indian rupees, according to analysts polled by FactSet.
Bajaj Consumer Care (BOM:533229, NSE:BAJAJCON) has an average rating of buy and mean price target of 564.25 Indian rupees, according to analysts polled by FactSet.
Indian benchmark indices ended higher on Friday as broad-based buying lifted markets, supported by gains in consumer goods and oil & gas stocks.The BSE Sensex rose 504.86 points, or 0.7%, to close at 78,493.54, while the NSE Nifty 50 gained 156.80 points, or also 0.7%, to settle at 24,353.55.Sentiment improved on expectations of easing tensions in the Middle East. Reports of a possible progress in U.S.-Iran negotiations and a potential extension of the ceasefire supported risk appetite.A sharp decline in crude oil prices further supported the market.In corporate developments, Bajaj Consumer Care (NSE:BAJAJCON, BOM:533229) reported a rise in consolidated profit to 636.0 million rupees in the fiscal fourth quarter from 309.8 million rupees a year earlier.Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) received U.S. FDA approval to manufacture and market Glycerol Phenylbutyrate Oral Liquid. The product is equivalent to the reference drug Ravicti and will be launched immediately, the company said in a Friday filing.
Bajaj Consumer Care's (NSE:BAJAJCON, BOM:533229) consolidated profit jumped to 636.0 million Indian rupees in the fiscal fourth quarter ended March 31, from 309.8 million rupees a year ago.Earnings per share grew to 4.75 rupees from 2.23 rupees a year earlier, the personal care products manufacturer said in a filing to the Indian stock exchanges on Friday.Revenue from operations in fiscal Q4 also increased to 3.27 billion rupees from 2.50 billion rupees a year ago.The company's shares surged over 13% in recent trade.
